Focus: JenaValve is a public medical device company headquartered in Irvine, CA, specializing in transcatheter aortic valve replacement (TAVR) systems for cardiovascular disease. The company focuses on innovative valve technologies for aortic stenosis and regurgitation indications.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Growing — net +10 jobs in 30d
10 jobs added vs 0 removed. Steady team buildout.
JenaValve offers specialized TAVR expertise in a focused cardiovascular niche, but the lack of open positions and opaque financial metrics present significant hiring uncertainty for prospective employees.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core platform addressing both stenosis and regurgitation in TAVR market with multiple clinical trials ongoing.
Help build intelligence for JenaValve
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from JenaValve's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Specialized valve system targeting aortic regurgitation with dedicated clinical trial program.
Foundational TAVR technology platform with clinical validation across multiple aortic valve pathologies.
JenaValve Makes History with First FDA-Approved Valve for Severe Aortic Regurgitation - The Healthcare Technology Report.
JenaValve Makes History with First FDA-Approved Valve for Severe Aortic Regurgitation The Healthcare Technology Report.
JenaValve secures FDA's 1st approval in aortic regurgitation - Fierce Biotech
JenaValve secures FDA's 1st approval in aortic regurgitation Fierce Biotech
8-K Filing: Edwards Lifesciences Corp (EW) (CIK 0001099800) — EX-99.1
EX-99.1
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 6 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo